Lung carcinoma is a common cause of mortality and morbidity worldwide. Non-small cell lung cancer (NSCLC) accounts for majority of cases worldwide. Accurate staging of NSCLC is of paramount importance due to marked difference in survival and management strategies between stage II and III of the disease. The staging methods have evolved from invasive thoracotomies and mediastinoscopies to relatively non-invasive complete mediastinal staging by combination of endoscopic ultrasound (EUS) and endoscopic bronchial ultrasound (EBUS). EUS also provides information about mediastinal invasion and liver/adrenal metastasis. Future role of EUS include providing tissue for molecular targeted therapy.
Carcinoma, Non-Small-Cell Lung* ; Endoscopic Ultrasound-Guided Fine Needle Aspiration ; Lung ; Mediastinoscopy ; Molecular Targeted Therapy ; Mortality ; Neoplasm Metastasis ; Thoracotomy ; Ultrasonography*

Endoscopic retrograde cholangiopancreatography (ERCP) is an invasive endoscopic technique that has many diagnostic and therapeutic implications. It is a procedure with small but significant life-threatening complications. To ensure the best possible care, minimize complications, and improve the quality of health care, a constant review of the performance of the operator using ideal benchmark standards is needed. Hence, quality indicators are necessary. The American and European Societies of Gastrointestinal Endoscopy have provided guidelines on quality measures for ERCP, which describe the skills to be developed and training to be implemented in performing quality ERCP. These guidelines have divided the indicators into pre-procedure, intraprocedural, and post-procedure measures. The focus of this article was to review the quality indicators of ERCP.

BACKGROUND/AIMS: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) cytology of adrenal masses helps in etiological diagnosis. The aim of this study was to evaluate the diagnostic yield of EUS-FNA of adrenal masses in cases where other imaging methods failed and/or were not feasible. METHODS: Twenty-one consecutive patients with adrenal masses, in whom adrenal FNA was performed because conventional imaging modalities failed and/or were not feasible, were prospectively evaluated over a period of 3 years. RESULTS: Of the 21 patients (mean age, 56+/-12.2 years; male:female ratio, 2:1), 12 had pyrexia of unknown origin and the other nine underwent evaluation for metastasis. The median lesion size was 2.4x1.6 cm. Ten patients were diagnosed with tuberculosis (shown by the presence of caseating granulomas [n=10] and acid-fast bacilli [n=4]). Two patients had EUS-FNA results suggestive of histoplasmosis. The other patients had metastatic lung carcinoma (n=6), hepatocellular carcinoma (n=1), and adrenal lipoma (n=1) and adrenal myelolipoma (n=1). EUS results were not suggestive of any particular etiology. No procedure-related adverse events occurred. CONCLUSIONS: EUS-FNA is a safe and effective method for evaluating adrenal masses, and it yields diagnosis in cases where tissue diagnosis is impossible or has failed using conventional imaging modalities.
Adrenal Glands* ; Biopsy, Fine-Needle* ; Carcinoma, Hepatocellular ; Diagnosis ; Endoscopic Ultrasound-Guided Fine Needle Aspiration ; Endosonography ; Fever ; Granuloma ; Histoplasmosis ; Humans ; Lipoma ; Lung ; Myelolipoma ; Neoplasm Metastasis ; Prospective Studies ; Tuberculosis